Sales Support Specialist
About the job
- Hands-on experience in supply chain, demand planning, or Sales and Operations Planning/Sales and Operations Execution processes, ideally in an international or multi-market environment.
- Experience with export logistics and international shipments.
- Experience facilitating or participating in cross-functional planning meetings such as Activity Review Meetings/Demand Review Meetings, and collaborating with Sales, Marketing, and Key Account Managers.
- Strong data analysis and forecasting skills.
- Proficiency in planning systems such as JDA or advanced planning tools, and advanced Excel/reporting.
- Regulatory and compliance awareness for export markets.
- A bachelor's or master's degree in Supply Chain Management, Logistics, Business Administration, Economics, Data Analytics, or a related field.
- Fluency in Russian and strong English.
- Coordinate operational support for the KZ and CCA region by managing market readiness and compliance requirements, overseeing export logistics, driving KPI reporting and analysis, and providing data-driven business insights for demand planning and operational performance.
- Work with the VAS specialist to ensure products for the customer region meet certification, labeling, stickering, Directions for Use, and other requirements.
- Prepare VAS requirements for new clients and markets, including specification alignment and delivery timelines.
- Act as the point of contact between KZ&CCA and CEE regions, providing actionable data analysis to support business cases and justify demand plans.
- Oversee shipments to partners in Kazakhstan and the CCA region.
- Create and align short-term demand plans for Customer Planning Groups using and improving the baseline forecast and incorporating relevant input from Sales, customers through collaborative forecasts, and Marketing.
- Consolidate sales data, marketing inputs, and consumer insights to support data-driven decision-making.
- Deliver relevant information and forecasts on time and develop strategies to mitigate risks related to demand fluctuations.
- Collaborate across functions to prepare accurate forecasts and monitor significant changes in sales forecasts, budgets, and business strategies.
- Collect inputs for short- and long-term phase-in/phase-out activities and promotions, incorporate them into the enrichment process, and assess feasibility from a supply chain capability perspective.
- Continuously improve the Sales and Operations Planning process and facilitate and lead monthly Activity Review Meetings/Demand Review Meetings.
- Support relevant functions in preparing and revising forecasts for Sales Review Meetings, and evaluate plans from local Key Account Managers.
- Analyze and interpret data and provide actionable recommendations to optimize planning processes.
- Monitor and analyze key performance indicators, including Forecast Accuracy, Customer Satisfaction Level, Fill Rate, bias, aging and excess stock, and end-of-year stock level.
- Follow up on major contributors and outliers, and develop and implement corrective actions to improve key performance indicators and overall process efficiency.
- Own and support reporting activities, including preparation, maintenance, backup coverage, and stakeholder coordination for operational reports such as ATP, LEAN, and PDCA.
- Conduct stock control analysis to flag allocation inconsistencies.
- Experience in supply chain, demand planning, or Sales and Operations Planning/Sales and Operations Execution processes in an international or multi-market environment is ideally preferred.
About the company
Philips makes medical equipment and software for hospitals and care providers, along with personal health products for consumers. Its hospital portfolio spans MRI and CT scanners, ultrasound, image-guided treatment systems and patient monitors, while Sonicare and Avent cover oral health and baby care. Clinical software connects medical images and patient data across care teams, and the company earns revenue from equipment, software, maintenance and consumer product sales. It works with health systems through long-term technology and service partnerships, including solutions for care at home. Founded in 1891, Philips is headquartered in Amsterdam, the Netherlands.
Company Size
10,001+
Company Stage
IPO
Headquarters
Andover, Minnesota
Founded
1891
Get referred to Philips
See people who can refer or advise you
Simplify's Take
What believers are saying
- Demand improved: Philips reported 4% comparable group sales growth for Q2 2026 in July 2026.
- Software expertise has room to develop: software and data science comprised about half Philips' research effort in 2025.
- Manufacturing expansion has backing: Philips reiterated a $150 million North American investment plan in February 2026.
What critics are saying
- US sleep-device sales remain restricted: Philips Respironics must meet consent-decree requirements before resuming new sleep-therapy device sales.
- Underlying earnings weakened: Philips' July 2026 report shows Q2 adjusted earnings fell slightly excluding its US tariff refund.
- Central teams face cost pressure: February 2026 plans target 15% to 20% lower central-function costs at Philips.
What makes Philips unique
- MRI avoids helium refills: Philips says its sealed BlueSeal magnets use seven liters rather than conventional systems' 1,500.
- Inventions form a substantial asset base: Philips reports 53,000 patent rights across its technology portfolio.
- The employer's name spans independent businesses: Philips licenses its brands across multiple product categories to outside partners.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.